Replimune Group, which is developing oncolytic immunotherapies to fight solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Woburn, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol REPL. Replimune Group filed confidentially on May 3, 2018. J.P. Morgan, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
